全文获取类型
收费全文 | 3793篇 |
免费 | 276篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 137篇 |
妇产科学 | 79篇 |
基础医学 | 678篇 |
口腔科学 | 15篇 |
临床医学 | 452篇 |
内科学 | 792篇 |
皮肤病学 | 52篇 |
神经病学 | 287篇 |
特种医学 | 96篇 |
外科学 | 457篇 |
综合类 | 20篇 |
一般理论 | 1篇 |
预防医学 | 428篇 |
眼科学 | 57篇 |
药学 | 201篇 |
中国医学 | 9篇 |
肿瘤学 | 312篇 |
出版年
2024年 | 4篇 |
2023年 | 16篇 |
2022年 | 59篇 |
2021年 | 130篇 |
2020年 | 73篇 |
2019年 | 122篇 |
2018年 | 84篇 |
2017年 | 56篇 |
2016年 | 84篇 |
2015年 | 96篇 |
2014年 | 150篇 |
2013年 | 207篇 |
2012年 | 278篇 |
2011年 | 302篇 |
2010年 | 172篇 |
2009年 | 177篇 |
2008年 | 244篇 |
2007年 | 268篇 |
2006年 | 233篇 |
2005年 | 236篇 |
2004年 | 230篇 |
2003年 | 206篇 |
2002年 | 252篇 |
2001年 | 33篇 |
2000年 | 24篇 |
1999年 | 34篇 |
1998年 | 51篇 |
1997年 | 33篇 |
1996年 | 27篇 |
1995年 | 25篇 |
1994年 | 19篇 |
1993年 | 18篇 |
1992年 | 14篇 |
1991年 | 6篇 |
1990年 | 8篇 |
1989年 | 16篇 |
1988年 | 7篇 |
1987年 | 5篇 |
1986年 | 14篇 |
1985年 | 7篇 |
1984年 | 15篇 |
1982年 | 7篇 |
1981年 | 7篇 |
1980年 | 6篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1970年 | 2篇 |
1969年 | 2篇 |
1967年 | 2篇 |
1964年 | 2篇 |
排序方式: 共有4085条查询结果,搜索用时 31 毫秒
991.
Hensley ML Kravetz S Jia X Iasonos A Tew W Pereira L Sabbatini P Whalen C Aghajanian CA Zarwan C Berlin S 《Cancer》2012,118(9):2403-2410
BACKGROUND:
Eribulin mesylate is a tubulin inhibitor with activity superior to paclitaxel in NIH:OVCAR‐3 human epithelial ovarian cancer xenograft models. In this study, the authors assessed the efficacy of eribulin in platinum‐resistant and platinum‐sensitive recurrent ovarian cancer.METHODS:
Patients with recurrent, measurable epithelial ovarian cancer who had received ≤2 prior cytotoxic regimens and who had adequate organ function were enrolled into 2 separate cohorts: 1) platinum‐resistant patients (who had a progression‐free interval <6 months after their last platinum‐based therapy) and 2) platinum‐sensitive patients (who had a progression‐free interval ≥6 months after their last platinum‐based therapy). Eribulin 1.4 mg/m2 was administered over 15 minutes intravenously on days 1 and 8 every 21 days. Efficacy was determined by objective response on computed tomography studies.RESULTS:
In the platinum‐resistant cohort, 37 patients enrolled, and 36 patients were evaluable for response and toxicity. Two patients achieved a partial response (5.5%), and 16 patients (44%) had stable disease as their best response. The median progression‐free survival was 1.8 months (95% confidence interval, 1.4‐2.8 months). In the platinum‐sensitive cohort, 37 patients enrolled, and all were evaluable for response. Seven patients achieved a partial response (19%). The median progression‐free survival was 4.1 months (95% confidence interval, 2.8‐5.8 months). The major toxicity was grade 3 or 4 neutropenia (42% of platinum‐resistant patients; 54% of platinum‐sensitive patients).CONCLUSIONS:
Eribulin produced an objective response in 5.5% of women with platinum‐resistant, recurrent ovarian cancer and in 19% of women with platinum‐sensitive disease. The median progression‐free survival was 1.8 months in the platinum‐resistant group and 4.1 months in the platinum‐sensitive group. Cancer 2012. © 2011 American Cancer Society. 相似文献992.
Italiano A Cioffi A Penel N Levra MG Delcambre C Kalbacher E Chevreau C Bertucci F Isambert N Blay JY Bui B Antonescu C D'Adamo DR Maki RG Keohan ML 《Cancer》2012,118(13):3330-3336
BACKGROUND:
Data regarding the role of anthracyclines and taxanes as first‐line treatments of metastatic angiosarcoma are limited.METHODS:
Records of 117 metastatic angiosarcoma patients who were treated with either doxorubicin or weekly paclitaxel were reviewed.RESULTS:
Seventy‐five patients (64%) were treated with weekly paclitaxel and 42 (36%) with single‐agent doxorubicin. Patients in the weekly paclitaxel group were older and more frequently had angiosarcomas arising from the skin. In the doxorubicin group, 34 patients were evaluable for response: 2 (6%) had complete response, 8 (23.5%) had partial response, 10 (29.5%) had stable disease, and 14 (41%) had progressive disease. In the weekly paclitaxel group, 68 patients were evaluable for response: 9 (13%) had complete response, 27 (40%) had partial response, 20 (29.5%) had stable disease, and 12 (17.5%) had progressive disease. Objective responses to weekly paclitaxel were more frequent in cutaneous angiosarcomas, whereas tumor location did not impact response to doxorubicin. Median progression‐free survival (PFS) was 4.9 months (95% confidence interval [95% CI], 3.9‐6.0 months). Median overall survival (OS) was 8.5 months (95% CI, 6.4‐10.7 months). On multivariate analysis, ECOG performance status (PS) was the sole independent factor associated with PFS and OS.CONCLUSIONS:
First‐line single‐agent doxorubicin and weekly paclitaxel seem to have similar efficacy in metastatic angiosarcomas. Cutaneous angiosarcomas respond favorably to weekly paclitaxel. Best supportive care should be considered in patients with poor PS. Cancer 2011. © 2011 American Cancer Society. 相似文献993.
Dominique Figarella-Branger Corinne Bouvier André Maues de Paula Karima Mokhtari Carole Colin Anderson Loundou Olivier Chinot Philippe Metellus 《Journal of neuro-oncology》2012,110(2):205-213
Adult grade II low-grade gliomas (LGG) are classified according to the WHO as astrocytomas, oligodendrogliomas or mixed gliomas. TP53 mutations and 1p19q codeletion are the main molecular abnormalities recorded, respectively, in astrocytomas and oligodendrogliomas and in mixed gliomas. Although IDH mutations (IDH1 or IDH2) are recorded in up to 85?% of low-grade gliomas, IDH negative gliomas do occur. We have searched for p53 expression, 1p19q codeletion and IDH status (immunohistochemical detection of the common R132H IDH1 mutation and IDH direct sequencing). Internexin alpha (INA) expression previously recorded to be associated with 1p19q codeletion (1p19q+) gliomas was also analysed. Low-grade gliomas were accurately classified into four groups: group 1, IDH+/p53?/1p19q?; group 2, IDH+/p53?/1p19q+; group 3, IDH+/p53+/1p19q?; and group 4, triple negative gliomas. In contrast to the WHO classification, this molecular classification predicts overall survival on uni- and multivariate analysis (P?=?0.001 and P?=?0.007, respectively). Group 4 carries the worst prognosis and group 2 the best. Interestingly, p53?+/INA? expression predicts lack of 1p19q codeletion (specificity 100?%, VPP 100?%). The combined use of these three molecular markers allow for an accurate prediction of survival in LGG. These findings could significantly modify LGG classification and may represent a new tool to guide patient-tailored therapy. Moreover, immunohistochemical detection of p53, INA and mR132H IDH1 expression could represent an interesting prescreening test to be performed before 1p19q codeletion, IDH1 minor mutation and IDH2 mutation detection. 相似文献
994.
Casasnovas RO Meignan M Berriolo-Riedinger A Itti E Huglo D Haioun C Morschhauser F 《Current hematologic malignancy reports》2012,7(3):193-199
The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP) criteria, primarily established for end of treatment evaluation, was related to a low positive predictive value of treatment failure. The 5-point scale (5PS) that refers the residual uptake to the liver as background tissue was shown to slightly reduce false-positive interim PET interpretations compared to IHP criteria. Semiquantification of fluorodeoxyglucose (FDG) uptake using standardized uptake value (SUV) and assessment of reduction of maximum SUV (SUVmax) between baseline and interim PET drastically improves both the interpretation accuracy and the interobserver reproducibility, and better predicts patient outcome than visual analysis. This latter approach is feasible in a multicenter setting and allows clinicians to design a risk-adapted therapeutic strategy based on early PET response assessment. 相似文献
995.
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Sebban C Mounier N Brousse N Belanger C Brice P Haioun C Tilly H Feugier P Bouabdallah R Doyen C Salles G Coiffier B 《Blood》2006,108(8):2540-2544
The purpose of this study is to compare our standard chemotherapy regimen (CHVP [cyclophosphamide, doxorubicin, teniposide, and prednisone]) plus interferon with 4 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by high-dose therapy with autologous stem cell transplantation (ASCT) in treatment-naive patients with advanced follicular lymphoma. Four hundred one patients were included from July 1994 to March 2001: 209 received 12 cycles of CHVP plus interferon alpha for 18 months (CHVP-I arm) and 192 received 4 cycles of CHOP followed by high-dose therapy (HDT) with total body irradiation and ASCT (CHOP-HDT arm). Overall response rates were similar in both groups (79% and 78% after induction chemotherapy, respectively). One hundred thirty-one of the 150 patients eligible for HDT underwent transplantation (87%). Intent-to-treat analysis after a median follow-up of 7.5 years showed that there was no difference between the 2 arms for overall survival (P = .53) or event-free survival (P = .11). Patients with a complete response at the end of the induction therapy had a statistically longer event-free survival and overall survival (P = .02 and < .001, respectively). After long-term follow-up, our study showed that there was no statistically significant benefit in favor of first-line high-dose therapy in patients with follicular lymphoma. High-dose therapy should be reserved for relapsing patients. 相似文献
996.
Salar A Haioun C Rossi FG Duehrsen U Pettengell R Johnsen HE Jaeger U Verhoef G Schwenkglenks M Bacon P Bendall K Lugtenburg PJ 《Leukemia research》2012,36(5):548-553
Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery. 相似文献
997.
998.
Frati A Chereau E Coutant C Bezu C Antoine M Chopier J Daraï E Uzan S Gligorov J Rouzier R 《Breast cancer research and treatment》2012,132(2):601-607
The aim of this study is to compare two published nomograms, the “Institut Gustave Roussy/M.D. Anderson Cancer Center” (IGR/MDACC)
and the Colleoni nomograms, in predicting pathologic complete responses (pCR) to preoperative chemotherapy in an independent
cohort and to assess the impact of HER2 status. Data from 200 patients with breast carcinoma treated with preoperative chemotherapy
were collected. We calculated pCR rate predictions with the two nomograms and compared the predictions with the outcomes.
Sixty percent of the patients with HER2-positive tumors received trastuzumab concomitantly with taxanes. Model performances
were quantified with respect to discrimination and calibration. In the whole population, the area under the ROC curve (AUC)
for the IGR/MDACC nomogram and the Colleoni nomogram were 0.74 and 0.75, respectively. Both of them underestimated the pCR
rate (P = 0.026 and 0.0005). When patients treated with trastuzumab were excluded, the AUC were excellent: 0.78 for both nomograms
with no significant difference between the predicted and the observed pCR (P = 0.14 and 0.15). When the specific population treated with trastuzumab preoperatively was analyzed, the AUC for the IGR/MDACC
nomogram and the Colleoni nomogram were poor, 0.52 and 0.53, respectively. The IGR/MDACC and the Colleoni nomograms were accurate
in predicting the probability of pCR after preoperative chemotherapy in the HER2-negative population but did not correctly
predict pCR in the HER2-positive patients who received trastuzumab. This suggests that responses to preoperative chemotherapy,
including trastuzumab, are biologically driven and that a specific nomogram or predictor for HER2-positive patients has to
be developed. 相似文献
999.
Foss F Horwitz SM Coiffier B Bartlett N Popplewell L Pro B Pinter-Brown LC Shustov A Furman RR Haioun C Koutsoukos T O'Connor OA 《Clinical Lymphoma, Myeloma & Leukemia》2012,12(4):238-243
BackgroundTransformed mycosis fungoides (tMF) is an aggressive disease, with poor prognosis and a median survival of 24 months.Patients And MethodsIn the Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PROPEL) study, 12 patients with tMF were treated with a median of 10 pralatrexate doses (starting dose of 30 mg/m2) administered weekly for 6 weeks in a 7-week cycle. The median number of prior systemic therapies was 3.ResultsThis retrospective analysis showed that the objective response rate in this subgroup was 25% (n = 3) per independent central review and 58% (n = 7) per investigator assessment, with this discrepancy likely attributed to challenges with photodocumentation of cutaneous lesions. The median duration of response and the median progression-free survival were 2.2 and 1.7 months, respectively, per central review, whereas median duration of response was 4.4 months, and median progression-free survival was 5.3 months per investigator assessment. Median survival was 13 months. Grade 1-3 mucositis was reported in 7 (58%) patients. Grade 4 adverse events were fatigue (n = 1) and thrombocytopenia (n = 1). Pralatrexate was well tolerated, with no toxicity-related discontinuations.ConclusionsBased on these results, pralatrexate may be a treatment option for patients with relapsed or refractory tMF. 相似文献
1000.
Shi J Tian J Pritchard A Lendon C Lambert JC Iwatsubo T Mann DM 《Acta neuropathologica》2006,111(1):15-20
It is presently unclear whether polymorphic variations in the oxidized low-density lipoprotein receptor 1 (OLR1), or low-density lipoprotein receptor-related protein 1 (LRP1), genes act as risk factors for Alzheimers disease (AD). In the present study, we have investigated the extent of amyloid protein (A) deposition as cerebral amyloid angiopathy (CAA) or senile plaques (SP) in relationship to OLR1 +1071 and +1073 polymorphisms and LRP1 C766T polymorphism in patients with AD There was an increased A40 load as CAA, but not as SP, in frontal cortex of AD patients carrying OLR1+1073 CC genotype, compared to those with CT, TT or CT+TT genotypes, but only in those individuals without apolipoprotein (APOE) 4 allele. No differences in total A or A42 load as CAA or SP between OLR1+1073 genotypes was seen, nor were there any differences between OLR1+1071 and LRP1 genotypes for any measure of A. Present data suggests that homozygosity for the C allele for OLR1+1073 polymorphism, selectively in individuals without APOE 4 allele, may impair clearance of A, and particularly A40, from the brain across the blood-brain barrier, leading to its diversion into perivascular drainage channels, thereby increasing the severity of CAA in such persons. 相似文献